Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
Wael Hafez, Husam Saleh, Ziad Al Baha, Mishal Tariq, Samah Hamdan, Shougyat Ahmed
Antibiotics, doi:10.3390/antibiotics11040498
1) Background: The WHO identified COVID-19 as a fast-growing epidemic worldwide. A few antivirals have shown promising effectiveness in treating COVID-19. This study aimed to assess the correlation between antiviral drugs and the time until viral clearance of SARS-CoV-2. (2) Methods: This was a retrospective cohort study that included 1731 non-severe COVID-19 patients treated in NMC Royal Hospital, UAE. (3) Results: A total of 1446 patients received symptomatic treatment only (mean age of 35.6 ± 9.0 years). The analyzed antiviral treatment protocols were azithromycin, hydroxychloroquine, lopinavir/ritonavir, and favipiravir. The produced Kaplan-Meier plots showed no significant differences in the time until viral clearance among the compared protocols, which showed overlapping confidence intervals, which were determined by performing the log-rank and adjusted pairwise log-rank tests (p = 0.2, log-rank = 9.3). The age and gender of patients did not significantly affect the rate of viral clearance regardless of the antiviral therapy administered, even when compared to patients who received symptomatic treatment only, with the exception of hydroxychloroquine (HCQ), azithromycin, and favipiravir, which increased the odds of a faster rate of viral clearance by 46% after adjustments. (4) Conclusions: No significant differences were observed regarding the time until viral clearance among non-severe COVID-19 patients following the prescription of different antiviral drugs.
References
Alhumaid, Al Mutair, Al Alawi, Alhmeed, Zaidi et al., Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis, Trop. Med. Infect. Dis,
doi:10.3390/tropicalmed5040180Badu, Oyebola, Zahouli, Fagbamigbe, De Souza et al., SARS-CoV-2 Viral Shedding and Transmission Dynamics: Implications of WHO COVID-19 Discharge Guidelines, Front. Med,
doi:10.3389/fmed.2021.648660Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Eng. Beijing China,
doi:10.1016/j.eng.2020.03.007Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2001282Chan, Yao, Yeung, Deng, Bao et al., Treatment with Lopinavir/Ritonavir or Interferon-B1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset, J. Infect. Dis,
doi:10.1093/infdis/jiv392Chen, Hu, Zhang, Jiang, Han et al., Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial, MedRxiv,
doi:10.1101/2020.03.22.20040758Chu, Cheng, Hung, Wong, Chan et al., Role of Lopinavir/Ritonavir in the Treatment of SARS: Initial Virological and Clinical Findings, Thorax,
doi:10.1136/thorax.2003.012658Corman, Albarrak, Omrani, Albarrak, Farah et al., Viral Shedding and Antibody Response in 37 Patients with Middle East Respiratory Syndrome Coronavirus Infection, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am,
doi:10.1093/cid/civ951De Wilde, Jochmans, Posthuma, Zevenhoven-Dobbe, Van Nieuwkoop et al., Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture, Antimicrob. Agents Chemother,
doi:10.1128/AAC.03011-14Devaux, Rolain, Colson, Raoult, New Insights on the Antiviral Effects of Chloroquine against Coronavirus: What to Expect for COVID-19?, Int. J. Antimicrob. Agents,
doi:10.1016/j.ijantimicag.2020.105938Ding, Li, Hong, Yu, Ye et al., Viral Kinetics and Factors Associated with Rapid Viral Clearance during Lopinavir/Ritonavir-Based Combination Therapy in Non-Severe COVID-19 Patients, Eur. Rev. Med. Pharmacol. Sci,
doi:10.26355/eurrev_202005_21373Echeverría-Esnal, Martin-Ontiyuelo, Navarrete-Rouco, De-Antonio Cuscó, Ferrández et al., Azithromycin in the Treatment of COVID-19: A Review, Expert Rev. Anti Infect. Ther,
doi:10.1080/14787210.2020.1813024Furtado, Berwanger, Fonseca, Corrêa, Ferraz et al., Azithromycin in Addition to Standard of Care versus Standard of Care Alone in the Treatment of Patients Admitted to the Hospital with Severe COVID-19 in Brazil (COALITION II): A Randomised Clinical Trial, Lancet,
doi:10.1016/S0140-6736(20)31862-6Gagliardini, Cozzi-Lepri, Mariano, Taglietti, Vergori et al., No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison, Front. Pharmacol,
doi:10.3389/fphar.2021.621676Gastine, Pang, Boshier, Carter, Lonsdale et al., Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies, Clin. Pharmacol. Ther,
doi:10.1002/cpt.2223Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and Microbiological Effect of a Combination of Hydroxychloroquine and Azithromycin in 80 COVID-19 Patients with at Least a Six-Day Follow up: A Pilot Observational Study, Travel Med. Infect. Dis,
doi:10.1016/j.tmaid.2020.101663Guner, Hasanoglu, Kayaaslan, Aypak, Akinci et al., Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir, J. Infect. Public Health,
doi:10.1016/j.jiph.2020.12.017Kim, Iwanami, Oda, Fujita, Kuba et al., Incomplete Antiviral Treatment May Induce Longer Durations of Viral Shedding during SARS-CoV-2 Infection, Life Sci. Alliance,
doi:10.26508/lsa.202101049Kim, Ko, Kim, Kim, Kim et al., Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea, J. Korean Med. Sci,
doi:10.3346/jkms.2020.35.e86Klein, Sex Influences Immune Responses to Viruses, and Efficacy of Prophylaxis and Treatments for Viral Diseases, BioEssays News Rev. Mol. Cell. Dev. Biol,
doi:10.1002/bies.201200099Kocayi Git, Özmen, Süner, Tomak, Demir et al., Observational Study of the Effects of Favipiravir vs Lopinavir/Ritonavir on Clinical Outcomes in Critically Ill Patients with COVID-19, J. Clin. Pharm. Ther,
doi:10.1111/jcpt.13305Li, Xie, Lin, Cai, Wen et al., Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial, Med,
doi:10.1016/j.medj.2020.04.001Million, Lagier, Gautret, Colson, Fournier et al., Early Treatment of COVID-19 Patients with Hydroxychloroquine and Azithromycin: A Retrospective Analysis of 1061 Cases in Marseille, France, Travel Med. Infect. Dis,
doi:10.1016/j.tmaid.2020.101738Pontali, Volpi, Antonucci, Castellaneta, Buzzi et al., Safety and Efficacy of Early High-Dose IV Anakinra in Severe COVID-19 Lung Disease, J. Allergy Clin. Immunol,
doi:10.1016/j.jaci.2020.05.002Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment with Hydroxychloroquine or Azithromycin with In-Hospital Mortality in Patients with COVID-19 in New York State, JAMA,
doi:10.1001/jama.2020.8630Salciccia, Eisenberg, Maggi, Lai, Mastroianni et al., Modeling the Contribution of Male Testosterone Levels to the Duration of Positive COVID Testing among Hospitalized Male COVID-19 Patients, Diagnostics,
doi:10.3390/diagnostics11040581Schrezenmeier, Dörner, Mechanisms of Action of Hydroxychloroquine and Chloroquine: Implications for Rheumatology, Nat. Rev. Rheumatol,
doi:10.1038/s41584-020-0372-xSheahan, Sims, Leist, Schäfer, Won et al., Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV, Nat. Commun,
doi:10.1038/s41467-019-13940-6Smith, Dodds, Bentley, Yeo, Rayner, Dosing Will Be a Key Success Factor in Repurposing Antivirals for COVID-19, Br. J. Clin. Pharmacol,
doi:10.1111/bcp.14314Totura, Bavari, Broad-Spectrum Coronavirus Antiviral Drug Discovery, Expert Opin. Drug Discov
Yan, Liu, Zhu, Huang, Dan et al., Factors Associated with Prolonged Viral Shedding and Impact of Lopinavir/Ritonavir Treatment in Hospitalised Non-Critically Ill Patients with SARS-CoV-2 Infection, Eur. Respir. J,
doi:10.1183/13993003.00799-2020Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am,
doi:10.1093/cid/ciaa237Zhao, Zhang, Zhu, Chen, Chen et al., Favipiravir in the Treatment of Patients with SARS-CoV-2 RNA Recurrent Positive after Discharge: A Multicenter, Open-Label, Randomized Trial, Int. Immunopharmacol,
doi:10.1016/j.intimp.2021.107702Zhou, Ding, Bao, Xue, Han et al., Clinical Features in Coronavirus Disease 2019 (COVID-19) Patients with Early Clearance and Prolonged Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA, Ann. Transl. Med,
doi:10.21037/atm-21-445Zhou, Yu, Du, Fan, Liu et al., Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study, Lancet
Zhu, Lu, Xu, Chen, Yang et al., Arbidol Monotherapy Is Superior to Lopinavir/Ritonavir in Treating COVID-19, J. Infect,
doi:10.1016/j.jinf.2020.03.060
